Physician profile
Anna M Small
NPI 1235172321
$2,968.98
in general payments reported to CMS, 2019-2025
30 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $357 · 2023: $539 · 2024: $876 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $402.91 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $369.36 | 2022-2025 | |
| Pfizer INC. | $264.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $170.92 | 2022-2024 | Rexulti |
| Abbott Laboratories | $169.08 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $167.25 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $150.20 | 2022-2025 | |
| Corcept Therapeutics | $133.26 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $118.45 | 2022-2024 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $65.10 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $61.77 | 2024-2025 | |
| Organon LLC | $59.75 | 2024 | |
| Lundbeck LLC | $55.22 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $47.93 | 2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.56 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $25.11 | 2025 | |
| Merck Sharp & Dohme LLC | $24.20 | 2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $23.87 | 2022 | |
| Tris Pharma INC | $23.48 | 2025 | Dyanavel Xr |
| Dynavax Technologies Corporation | $22.70 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.21 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $21.89 | 2025 | Daybue |
| Roche Diagnostics Corporation | $21.36 | 2025 | Cobas Liat Analyzer |
| Noven Therapeutics, LLC | $21.19 | 2023 | Secuado |
| Springworks Therapeutics, INC. | $18.63 | 2025 | Gomekli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.70 | 2022 | |
| Currax Pharmaceuticals LLC | $14.85 | 2025 | Contrave |
| Dexcom, INC. | $13.43 | 2022 | |
| Astellas Pharma US INC | $12.71 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.